Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (trading symbol: OCX) on November 14, 2019, regarding events occurring on November 13, 2019. The company is incorporated in California and is classified as an emerging growth company. The filing discloses the entry into a material definitive agreement for a private placement financing.
Key Financial Metrics
The filing details a specific financing transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Financing Amount: Approximately $8.6 million in aggregate cash purchase price.
- Shares Issued: 5,058,824 shares of common stock.
- Price Per Share: $1.70.
- Major Investor Participation: Broadwood Partners, L.P. (existing 22.9% beneficial owner) agreed to purchase 1,176,471 shares.
- Closing Date: Scheduled to occur no later than November 15, 2019.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity ratios outside of the context of this specific transaction.
Material Changes
The primary material change is the execution of Subscription Agreements with select institutional investors. This transaction represents a significant capital raise intended to fund company operations. The filing notes that the financing is being made pursuant to a registration statement on Form S-3 declared effective on June 18, 2019.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. Regarding risks and contingencies, the document includes standard legal disclaimers stating that representations, warranties, and covenants made in the Subscription Agreement were specific to the transaction date and should not be relied upon as characterizations of the actual state of facts or continuing intentions of the parties. Investors are cautioned that information concerning these representations may change after the date of the agreement.
Investor Verification Checklist
- Verify the actual closing of the financing and receipt of the $8.6 million proceeds by November 15, 2019.
- Review the definitive Subscription Agreement (Exhibit 10.1) for specific covenants, redemption rights, or liquidation preferences.
- Confirm the updated share count and dilution impact following the issuance of 5,058,824 new shares.
- Check subsequent filings for the prospectus supplement referenced in the S-3 registration statement.
- Monitor Broadwood Partners, L.P.'s updated beneficial ownership percentage post-transaction.